MIRUM PHARMACEUTICALS INC (MIRM)
Health Care · biotechnology · NASDAQ
Mirum Pharmaceuticals is a biopharmaceutical company specializing in the development and commercialization of innovative, minimally-absorbed therapies for rare cholestatic liver diseases.
What MIRUM PHARMACEUTICALS INC does
Mirum Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of therapies for rare liver diseases. The company markets three approved products: Livmarli, an ileal bile acid transporter (IBAT) inhibitor for cholestatic pruritus in patients with Alagille syndrome and PFIC; and bile acid medicines Cholbam and Ctexli for bile acid synthesis disorders and cerebrotendinous xanthomatosis. Its pipeline includes volixibat for primary sclerosing cholangitis and primary biliary cholangitis, and additional early-stage programs.
Themes: rare disease therapies, cholestatic liver disease, IBAT inhibitors, gastroenterology / hepatology
Fundamentals
- Price$85.07 as of 2026-10-20 close
- Market cap$5.5B as of 2026-07-31 (share count; price 2026-10-20)
- 1-year return+16.5% 2025-10-20 close $73.03 → 2026-10-20 close $85.07
- P/En/a negative earnings
- Net margin-4.5% FY2025, SEC XBRL
- ROEn/a shareholders' equity on the latest balance sheet is zero or negative, so a return on it is not meaningful
- ROICn/a No figure: its pre-tax income was zero or negative, so there is no tax rate to apply.
- Debt / equityn/a No figure: its filing reports debt under a line we do not read, so a total would be understated.
- Revenue growth (YoY)+54.7% FY2025, SEC XBRL
- Revenue CAGR (3y)+89.1% SEC XBRL
- Beta0.85 as of 2026-09-03
- Last reported earnings2026-08-05 SEC EDGAR Form 8-K (Item 2.02)
How MIRM compares in its sector
- net profit marginmiddle range 430 covered Health Care peers, as of 2026-09-03
- operating marginmiddle range 417 covered Health Care peers, as of 2026-09-03
- return on equitymiddle range 510 covered Health Care peers, as of 2026-09-03
- 3-year revenue CAGRtop 10% 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)middle range 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Quarterly results
| Quarter | Revenue | Operating income | Net income | Diluted EPS | Operating cash flow | Capex |
|---|---|---|---|---|---|---|
| Q2 FY2026 2026-06-30 | $176M | -$43M | -$67M | -$1.06 | -$44M† | $23000† |
| Q1 FY2026 2026-03-31 | $160M | -$789M | -$790M | -$13.43 | -$229M | $664000 |
| Q4 FY2025 2025-12-31 | $149M† | -$5M† | -$6M† | -$0.12† | $6M† | $600000† |
| Q3 FY2025 2025-09-30 | $133M | $3M | $3M | $0.05 | $40M† | $187000† |
| Q2 FY2025 2025-06-30 | $128M | -$5M | -$6M | -$0.12 | $12M† | $126000† |
| Q1 FY2025 2025-03-31 | $112M | -$15M | -$15M | -$0.30 | -$2M | $41000 |
| Q4 FY2024 2024-12-31 | $99M† | -$24M† | -$24M† | -$0.49† | -$5M† | $20000† |
| Q3 FY2024 2024-09-30 | $90M | -$13M | -$14M | -$0.30 | $4M† | $181000† |
† Not filed as a discrete quarter: derived from the company's own year-to-date figures (for example the fourth quarter as the fiscal year minus the first nine months). A derived per-share figure is approximate, because the share count moves within the year.
Balance sheet at 2026-06-30
- Cash and equivalents$331M
- Short-term investments$108M
- Total debtnot shown the filing reports its long-term debt in a form we do not read yet
From the company's own SEC 10-Q and 10-K filings (XBRL), re-read every week. Figures in US dollars as filed; informational only — not financial advice.
How MIRUM PHARMACEUTICALS INC looks technically
MIRUM PHARMACEUTICALS INC (MIRM) is trading 13.3% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 12 trading days ago — a "death cross", a bearish long-term signal. A strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 32, with sellers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 47, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bullish about 7 trading days ago (its momentum flipped positive). It made a new 20-day low about 11 trading days ago. It is 34.6% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 13.3% below its 200-day average, the long-term trend line — a long-term downtrend | -13.3% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $92.41 | $92.41 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $98.17 | $98.17 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing high 8 calendar days ago — the swings before that are what the structure reading is measured on | 8 sessions |
| Wave structure | its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 5 of five; the labelling fails if price closes above 88.31. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible downward five-wave sequence, in wave 5 (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 12 trading days ago — a "death cross", a bearish long-term signal | 12 sessions |
| Trend strength (14-day ADX) | a strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 32, with sellers in control | 32.2 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 47, neither overbought (above 70) nor oversold (below 30) | 47.0 |
|---|---|---|
| Position in its 14-day range | it is trading in the upper half of its 14-day range ($77.78 to $88.31) — its "stochastic" reading is 69 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 69.2 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bullish about 7 trading days ago (its momentum flipped positive) | 7 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $130.00 | $130.00 |
|---|---|---|
| From the 52-week high | it is 34.6% below its 52-week high (its highest price of the past year) | -34.6% |
| Above the 52-week low | it is 34.5% above its 52-week low (its lowest price of the past year) | +34.5% |
| Below the 52-week high | it is 34.6% below its highest point of the past year | 34.6% |
| Since a 20-day breakout | it made a new 20-day low about 11 trading days ago | 11 sessions |
| Since a 55-day breakout | it made a new 55-day low about 11 trading days ago | 11 sessions |
| All-time high | its highest closing price on record is $130.00 (set on 2026-07-09) | $130.00 |
| Given back of the 52-week move | over the past year its closes ranged ($64.10 to $128.57), and it has given back well over two thirds of its rise from last year’s low — 67% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $86.66 to $88.73. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 67.5% |
| From the all-time high | it is 34.6% below its all-time high | -34.6% |
| Nearest price level | it is trading 0.5% above a support level at $84.64 — a price it turned at twice since 2026-03-09, most recently on 2026-03-24. Since 2024-10-21 it has 10 such levels below the current price and 4 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -0.5% |
| All-time low | its lowest closing price on record is $6.51 (set on 2019-11-20) | $6.51 |
| Above the all-time low | it is 1206.2% above its all-time low | +1,206% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 32nd percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $4.02 between its high and its low — about 4.7% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $4.02 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $77.18 and $90.86 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $77.18 – $84.02 – $90.86 |
| Typical daily range (% of price) | its price moves about 4.7% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 4.7% |
| Stretch from the 200-day average | it is trading 3.3 daily ranges below its 200-day average price (13.3% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 3.3 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.75× |
|---|
Analyst
2
| Change in the average price target | analysts have raised their average price target by 5.0% since the prior reading | +5.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
1
| Since a bearish engulfing | 2 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 2 sessions ago |
|---|
Price gaps
3
| Gap at the open | it opened on 2026-10-20 0.6% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and had not traded back through that level by the close | +0.6% |
|---|---|---|
| Open gap | it gapped 14.7% below the previous close 52 sessions ago and has not traded back through the level it left behind at 105.79 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | -14.7% |
| Gap filled | a 2.7% gap up opened on 2026-10-15 has been "filled" 2 sessions ago — price traded back through the level the gap left behind, and it took 1 session to close | 2 sessions ago |
Price streaks
1
| Closing streak | it has closed higher 2 sessions in a row, a +6.15% move over the run — an unbroken run of up days, which describes what has already happened and says nothing about the next session | 2 sessions up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 8.3 percentage points (the stock lost 7.4% while the market gained 1.0%) | -8.3% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 30.7 percentage points (the stock lost 27.1% while the market gained 3.6%) | -30.7% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 19.6 percentage points (the stock lost 11.1% while the market gained 8.5%) | -19.6% |
| vs market, 12 months | over the past 12 months this stock beat the market by 1.9 percentage points (the stock gained 16.5% while the market gained 14.6%) | +1.9% |
Signal agreement
2
| Bullish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bullish state: MACD momentum is positive — these describe past price behaviour, not a forecast | 1 of 9 |
|---|---|---|
| Bearish technical signals | 5 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, trading below its 200-day average, a strong downtrend, with sellers in control, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 5 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 15% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-14 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is thick, spanning 11.5% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | -14.7% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 14% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $98.81 — a volume-weighted average of daily closes over 196 sessions, not a true tick-by-tick VWAP. | -13.9% |
|---|---|---|
| Vs the average paid since it last reported | the price is 7% below the average price paid since it last reported on 2026-08-05 (its 10-Q), so the typical buyer over that stretch is under water. That average is $91.87 — a volume-weighted average of daily closes over 54 sessions, not a true tick-by-tick VWAP. | -7.4% |
Price levels it has turned at before
MIRM last closed at $85.07 on 2026-10-20. Since 2024-10-21 it has turned at 10 prices below its last close and 4 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $84.64 | Support | 0.5% below the last close | turned there twice · 2026-03-09 to 2026-03-24 |
| $88.51 | Resistance | 4.0% above the last close | turned there three times · 2026-05-04 to 2026-10-12 |
| $90.30 | Resistance | 6.1% above the last close | turned there twice · 2026-04-24 to 2026-06-03 |
| $78.14 | Support | 8.2% below the last close | turned there three times · 2025-09-08 to 2026-10-06 |
| $74.42 | Support | 12.5% below the last close | turned there three times · 2025-11-12 to 2026-01-05 |
| $97.07 | Resistance | 14.1% above the last close | turned there twice · 2026-02-06 to 2026-03-17 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 5 of five.
This labelling fails — stops being a possible reading at all — if it closes above $88.31.
It is the only labelling that fits these swings, though its proportions are not the textbook ones. It was chosen from 3 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $21.78 and $62.90 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
This reading has stood for 2 trading days, since 2026-10-19.
Read from daily closes as of 2026-10-20.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Trading below the 50-day moving average · Recent death cross (50-day crossed below 200-day) · Pulled back from the 12-month high · Analyst price target recently RAISED · lagging the market | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low
Based on daily closing prices as of 2026-10-20. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.29 mean, 1=Strong Buy…5=Strong Sell) — 14 analysts
- Mean price target$153.07 range $118.00 – $200.00; median $153.00
Analyst estimates, as of 2026-10-17. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for MIRM
- Consensus EPS estimate-$0.425 next reporting period, as of 2026-10-17
- Estimate change, 30 days$0.00 from -$0.425, on 2026-09-12, 35-day window
- Readings revised upward0% of 9 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Dependence on successful commercialization of currently approved and future therapies.","Risks associated with clinical trial outcomes and regulatory approval timelines for pipeline candidates.","History of operating losses and the need for additional capital to fund operations."]
What changed in the latest 10-Q
AI-assisted comparison of MIRM's 10-Q filed 2026-05-06 against the prior one filed 2025-11-04.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-05-06) references Annual Report for year ended December 31, 2025, filed February 25, 2026
- Newer filing adds that Livmarli approved for cholestatic pruritus in PFIC in Canada and Japan
- Newer filing adds volixibat Breakthrough Therapy designation specifically 'as a potential treatment for cholestatic pruritus in patients with PBC' (October 2024)
- Newer filing reports VISTAS Phase 2b topline results announced May 2026
- Newer filing states NDA submission expected second half of 2026 for volixibat in PSC
- Newer filing states approval and launch expected first half of 2027 for volixibat in PSC
- Newer filing reports VANTAGE Phase 2b enrollment expected to complete second half of 2026 with topline data first quarter of 2027
- Newer filing states EXPAND study completed enrollment in first half of 2026 with topline data expected fourth quarter of 2026
- Newer filing adds acquisition of Bluejay Therapeutics completed January 23, 2026, including brelovitug (BJT-778)
- Newer filing adds brelovitug details: fully human IgG1 monoclonal antibody for chronic hepatitis D virus, FDA Breakthrough Therapy and EMA PRIME designations
- Newer filing adds AZURE clinical program with AZURE-1 and AZURE-4 topline results expected second half of 2026
- Newer filing adds AZURE-2 and AZURE-3 topline results expected first half of 2028
- Newer filing adds BLA submission expected first half of 2027 for brelovitug
- Newer filing adds potential approval and launch second half of 2027 for brelovitug in U.S.
- Newer filing adds April 2026 agreement with Incyte for zilurgisertib commercialization rights
- Newer filing adds zilurgisertib is oral small molecule ALK2 inhibitor for fibrodysplasia ossificans progressiva
- Newer filing adds FDA accepted Incyte NDA with PDUFA date September 26, 2026 for zilurgisertib
- Removed:
- Older filing (2025-11-04) references Annual Report for year ended December 31, 2024, filed February 26, 2025
- Older filing lists product as 'CHENODAL® or CTEXLI®' (removed 'CHENODAL' reference in newer)
- Older filing states Livmarli approved for PFIC in U.S. only (no Canada or Japan mentioned)
- Older filing describes chenodiol as 'standard of care' and previously commercialized as 'Chenodal'
- Older filing includes detailed history of Travere Therapeutics asset acquisition (August 31, 2023)
- Older filing states EXPAND study expected to complete enrollment in 2026 with topline in first half of 2027
- Older filing states VISTAS completed enrollment third quarter 2025 with topline expected second quarter 2026
- Older filing states VANTAGE expected to complete enrollment in 2026 with topline in first half of 2027
- Older filing states Phase 2 multi-dose safety and efficacy trial for MRM-3379 'has begun enrolling patients'
- Older filing includes 'Financial Overview' section with specific financial metrics for periods ended September 30, 2025 and 2024
- Reworded:
- Older: 'received approval from the Japanese Ministry' changed to newer: 'received approval from the Japanese Ministry of Health, Labour, and Welfare' (addition of full ministry name)
- Older: 'A Phase 2 multi-dose safety and efficacy trial has begun enrolling patients' changed to newer: 'We are currently enrolling patients in the BLOOM Phase 2 clinical study' (addition of study name BLOOM)
- Older: License agreement date stated as 'October 22, 2024' changed to newer: 'October 2024' (less specific)
- Older: 'We intend to develop MRM-3379 for the treatment of Fragile-X Syndrome' changed to newer: 'for the treatment of Fragile-X Syndrome' with addition of 'and expect topline data in 2027'
- Older: Refers to 'VISTAS Phase 2b clinical trial' enrollment completion timing; newer specifies 'topline results announced May 2026'
- Older: Includes Travere asset purchase agreement details; newer: omits this historical information entirely
- Notes:
- The older filing text appears truncated at the end ('We anticipate we wi'), preventing full comparison of the Financial Overview section and any content that follows
- Dates for MRM-3379 development shifted from general '2026' completion in older filing to more specific 'topline data in 2027' in newer filing
- Older filing provides specific financial metrics (net income, accumulated deficit, cash) for September 30, 2025; these sections are not present in the provided excerpt of the newer filing
Risk Factors
The two filings could not be meaningfully compared for this section.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 10 open-market sales by insiders in the last 90 days, of which we have read Form 4 filings through 2026-10-16. The 6 days since 2026-10-16 have not been checked yet.
- Last 90 days · read to 2026-10-160 buys · 10 sells ($11M) — 3 selling insiders
- Last 180 days · read to 2026-10-160 buys · 31 sells ($18M) — 4 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-09-14. Based on Form 4 filings read through 2026-10-16; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about MIRM's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding MIRM as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 10,706,851
- Reported value $1,253,451,076
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 3 increased, 2 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about MIRM's institutional holders → See what each manager we track holds →
Short interest (FINRA)
MIRM had 6,985,385 shares of reported short interest as of the 2026-09-30 FINRA settlement date (delayed, bi-monthly; not real-time).
MIRM had 10.8% of its shares outstanding sold short as of the 2026-09-30 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 7.67 days to cover at the same settlement.
- Reported short interest (shares) 6,985,385
- Short interest (% of shares outstanding) 10.8%
- Prior settlement (shares) 6,281,413
- Reported change 11.21%
- Days to cover (reported) 7.67
Reported to FINRA as of the 2026-09-30 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Albireo (acquired by Ipsen)
- Ipsen (IPSEY)
- Intercept Pharmaceuticals (acquired by Alfasigma)
- Travere Therapeutics (TVTX)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare MIRM vs…
Frequently asked questions
What does MIRUM PHARMACEUTICALS INC (MIRM) do?
Mirum Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of therapies for rare liver diseases. The company markets three approved products: Livmarli, an ileal bile acid transporter (IBAT) inhibitor for cholestatic pruritus in patients with Alagille syndrome and PFIC; and bile acid medicines Cholbam and Ctexli for bile acid synthesis disorders and cerebrotendinous xanthomatosis.
What sector is MIRUM PHARMACEUTICALS INC (MIRM) in?
MIRUM PHARMACEUTICALS INC (MIRM) is classified in the Health Care sector. Its industry is biotechnology. It trades on NASDAQ.
Who are MIRUM PHARMACEUTICALS INC's (MIRM) competitors?
Notable peers of MIRUM PHARMACEUTICALS INC (MIRM) include Albireo (acquired by Ipsen), Ipsen, Intercept Pharmaceuticals (acquired by Alfasigma) and Travere Therapeutics. This peer set is informational only — not financial advice.
Is MIRUM PHARMACEUTICALS INC (MIRM) overbought or oversold right now?
MIRUM PHARMACEUTICALS INC (MIRM) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 47, in the neutral middle (as of 2026-10-20). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on MIRM come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.